Mr. Daniel Cowell is a Co-Founder and serves as the Chief Executive Officer and Board Member at Psyomics. He is a Board Member of Sentinal Oncology. He served as Chief Operating Officer at Horizon Discovery. He co-founded Pharmorphix, a specialist CRO in the area of solid form, which grew market share rapidly and was subsequently acquired by Sigma Aldrich in 2006. Following the sale of Pharmorphix he founded Hypoxium, a client focused CRO providing pre-clinical oncology research which grew its revenue at over 75% each year. He was appointed COO of Horizon Discovery following Hypoxium's acquisition in 2010. He holds a BS in Chemistry from University of Kent.